PDF herunterladen
Horm Metab Res 2024; 56(03): 197-205
DOI: 10.1055/a-2231-8475
Original Article: Endocrine Care

Characteristics of Ovarian Cancer Immune Cell Invasion and Bioinformatics to Predict the Effect of Immunotherapy

Lingli Yan 
1   Department of Transfusion Medicine, West China Hospital of Sichuan University, Chengdu, China
,
Erxi Fan
2   Department of Ultrasound, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China
,
Bin Tan
1   Department of Transfusion Medicine, West China Hospital of Sichuan University, Chengdu, China
› Institutsangaben Fundings Sichuan Science and Technology Program No.2022NSFSC1513.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Recent studies have confirmed that tumor immune cell infiltration (ICI) is associated with sensitivity of ovarian cancer (OC) immunotherapy and disease progression of OC patients. However, studies related to immune infiltration in OC, has not been elucidated. Two algorithms are used to analyze the OC data in the TCGA and GEO databases. After combining the two data sets, the immune cell content of the sample was estimated by Cell-type Identification By Estimate Relative Subsets of RNA Transcripts (CIBERSORT method). An unsupervised consistent clustering algorithm was used to analyze ICI subtypes and their differentially expressed genes (DEGs). Two subgroups and three ICI gene clusters were identified by unsupervised consensus clustering algorithm. The ICI score was obtained by analyzing the gene characteristics through principal component analysis (PCA). The ICI score ranged from –15.8132 to 18.7211, which was associated with the prognosis of OC patients with immunotherapy. The Toll-like receptor pathway, B-cell receptor pathway, antigen processing and presentation pathway, NK-cell-mediated cytotoxicity pathway, and arginine-proline metabolism pathway were activated in the high ICI score group, suggesting that immune cells in the high ICI score group were activated, thus leading to a better prognosis in this group of patients. Patients with G3–G4 in the high ICI rating group were more sensitive to immunotherapy and had a better prognosis in patients with high tumor mutation burden (TMB). This study suggests that ICI scores can be used as a feasible auxiliary indicator for predicting the prognosis of patients with OC.

Key words

ovarian cancer - immune cell invasion - TCGA - bioinformatics - immunotherapy

Supplementary Material



Publikationsverlauf

Eingereicht: 04. Juli 2023

Angenommen nach Revision: 05. Dezember 2023

Artikel online veröffentlicht:
19. Januar 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Henderson JT, Webber EM, Sawaya GF. Screening for ovarian cancer: updated evidence report and systematic review for the US preventive services task force. JAMA 2018; 319: 595-606
    CrossrefPubMedGoogle Scholar
  • 2 Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med 2017; 14: 9-32
    CrossrefPubMedGoogle Scholar
  • 3 Alison EF, Jessica AB, Elizabeth LC. et al. Mechanisms of drug resistance in high-grade serous ovarian cancer. Hematol Oncol Clin North Am 2018; 32: 983-996
    CrossrefPubMedGoogle Scholar
  • 4 Saleh R, Elkord E. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. Semin Cancer Biol 2020; 65: 13-27
    CrossrefPubMedGoogle Scholar
  • 5 Sanmamed MF, Chen L. A Paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell 2019; 176: 677
    CrossrefPubMedGoogle Scholar
  • 6 Liu JF, Gordon M, Veneris J. et al. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol 2019; 154: 314-322
    CrossrefPubMedGoogle Scholar
  • 7 Disis ML, Taylor MH, Kelly K. et al. Efficacy and safety of Avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol 2019; 5: 393-401
    CrossrefPubMedGoogle Scholar
  • 8 Matulonis UA, Shapira-Frommer R, Santin AD. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol 2019; 30: 1080-1087
    CrossrefPubMedGoogle Scholar
  • 9 Odunsi K. Immunotherapy in ovarian cancer. Ann Oncol 2017; 28: viii1-viii7
    CrossrefPubMedGoogle Scholar
  • 10 Choucair K, Morand S, Stanbery L. et al. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. Cancer Gene Ther 2020; 27: 841-853
    CrossrefPubMedGoogle Scholar
  • 11 Papaioannou NE, Beniata OV, Vitsos P. et al. Harnessing the immune system to improve cancer therapy. Ann Transl Med 2016; 4: 261
    CrossrefPubMedGoogle Scholar
  • 12 Dominique CH, Lalita AS. The Tumor microenvironment innately modulates cancer progression. Cancer Res 2019; 79: 4557-4566
    CrossrefPubMedGoogle Scholar
  • 13 Xian JJ, Jie W, Xiang YD. et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer 2019; 18: 10
    CrossrefPubMedGoogle Scholar
  • 14 Keenan TE, Burke KP, Van AE. Genomic correlates of response to immune checkpoint blockade. Nat Med 2019; 25: 389-402
    CrossrefPubMedGoogle Scholar
  • 15 Drakes ML, Stiff PJ. Regulation of ovarian cancer prognosis by immune cells in the tumor microenvironment. Cancers (Basel) 2018; 10: 302
    CrossrefPubMedGoogle Scholar
  • 16 Rick K, Rita DB, Bianca JB. et al. Sequencing in oncology: genetic diagnosis, risk prediction and cancer classification. Int J Mol Sci 2017; 18: 308
    CrossrefPubMedGoogle Scholar
  • 17 Ming C, Hong YZ. Next-generation sequencing in liquid biopsy: cancer screening and early detection. Hum Genomics 2019; 13: 34
    CrossrefPubMedGoogle Scholar
  • 18 Newman AM, Liu CL, Green MR. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 2015; 12: 453-457
    CrossrefPubMedGoogle Scholar
  • 19 Yoshihara K, Shahmoradgoli M, Martínez E. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 2013; 4: 2612
    CrossrefPubMedGoogle Scholar
  • 20 Wagner GP, Kin K, Lynch VJ. Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples. Theory Biosci 2012; 131: 281-285
    CrossrefPubMedGoogle Scholar
  • 21 Yu G, Wang LG, Han Y. et al. ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 2012; 16: 284-287
    CrossrefPubMedGoogle Scholar
  • 22 David CC, Jacobs DJ. Principal component analysis: a method for determining the essential dynamics of proteins [J]. Meth Mol Biol (Clifton, N.J.) 2014; 1084: 193-226
    CrossrefPubMedGoogle Scholar
  • 23 Kursa MB, Rudnicki WR. Feature selection with the Boruta package. J Stat Softw 2010; 36: 1-13
    CrossrefPubMedGoogle Scholar
  • 24 Sotiriou C, Wirapati P, Loi S. et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98: 262-272
    CrossrefPubMedGoogle Scholar
  • 25 Mayakonda A, Lin DC, Assenov Y. et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res 2018; 28: 1747-1756
    CrossrefPubMedGoogle Scholar
  • 26 Fernanda GH, Melita I, Lana EK. et al. Rational combinations of immunotherapy with radiotherapy in ovarian cancer. Lancet Oncol 2019; 20: e417-e433
    CrossrefPubMedGoogle Scholar
  • 27 Basheerulla S, Tabassum Z, Krishnan B. et al. An overview of ovarian cancer: molecular processes involved and development of target-based chemotherapeutics. Curr Top Med Chem 2021; 21: 329-346
    CrossrefPubMedGoogle Scholar
  • 28 Carsten G, Günter E. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Cells 2021; 10: 437
    CrossrefPubMedGoogle Scholar
  • 29 Huiyan C, Zhichao W, Lifeng C. et al Opportunities and challenges of the human microbiome in ovarian cancer. Front Oncol 2020 10: 163 eCollection 2020;
    PubMedGoogle Scholar
  • 30 Li H, Wu N, Liu ZY. et al. Development of a novel transcription factors-related prognostic signature for serous ovarian cancer. Sci Rep 2021; 11: 7207
    CrossrefPubMedGoogle Scholar
  • 31 Zhao S, Ma D, Xiao Y. et al. Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance. Oncologist 2020; 25: e1481-e1491
    CrossrefPubMedGoogle Scholar
  • 32 Efstathiou JA, Mouw KW, Gibb EA. et al. Impact of immune and stromal infiltration on outcomes following bladder-sparing trimodality therapy for muscle-invasive bladder cancer. Eur Urol 2019; 76: 59-68
    CrossrefPubMedGoogle Scholar
  • 33 Collisson EA, Bailey P, Chang DK. et al. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol 2019; 16: 207-220
    CrossrefPubMedGoogle Scholar
  • 34 Choucair K, Morand S, Stanbery L. et al. Nemunaitis, J. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. Cancer Gene Ther 2020; 27: 841-853
    CrossrefPubMedGoogle Scholar
  • 35 Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 2017; 377: 2500-2501
    CrossrefPubMedGoogle Scholar
  • 36 Yarchoan M, Albacker LA, Hopkins AC. et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 2019; 4: e126908
    CrossrefPubMedGoogle Scholar